Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,483
  • Shares Outstanding, K 23,198
  • Annual Sales, $ 90 K
  • Annual Income, $ -39,910 K
  • 60-Month Beta 4.74
  • Price/Sales 1,836.96
  • Price/Cash Flow N/A
  • Price/Book 1.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.51
  • Number of Estimates 3
  • High Estimate -0.50
  • Low Estimate -0.52
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -15.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.87 +9.54%
on 11/08/19
8.83 -27.18%
on 10/21/19
-1.06 (-14.09%)
since 10/11/19
3-Month
5.87 +9.54%
on 11/08/19
12.51 -48.60%
on 08/21/19
-4.56 (-41.49%)
since 08/13/19
52-Week
2.75 +133.82%
on 12/31/18
16.47 -60.96%
on 05/17/19
+1.06 (+19.74%)
since 11/13/18

Most Recent Stories

More News
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc.- ZYNE

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) from March 11, 2019 through September...

ZYNE : 6.58 (+0.77%)
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 6.58 (+0.77%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zynerba Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline- ZYNE

Pomerantz LLP announces that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc. ("Zynerba" or the "Company") (NASDAQ: ZYNE) and certain of its officers. The class action, filed...

ZYNE : 6.58 (+0.77%)
SHAREHOLDER ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 23, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc. ("Zynerba" or the "Company") (ZYNE) and certain...

ZYNE : 6.58 (+0.77%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zynerba, iRobot, Zendesk, and Abeona and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Zynerba Pharmaceuticals, Inc. (NASDAQ:...

ZYNE : 6.58 (+0.77%)
IRBT : 47.37 (-0.65%)
ZEN : 73.86 (+0.48%)
ABEO : 2.42 (+5.68%)
Zynerba: 3Q Earnings Snapshot

DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $1.9 million in its third quarter.

ZYNE : 6.58 (+0.77%)
Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

- Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel(TM) in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability...

ZYNE : 6.58 (+0.77%)
Zynerba Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - November 5, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) ("Zynerba" or...

ZYNE : 6.58 (+0.77%)
Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $7.44, marking a -0.53% move from the previous day.

ZYNE : 6.58 (+0.77%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zynerba Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ZYNE

Pomerantz LLP announces that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc. ("Zynerba" or the "Company") (NASDAQ: ZYNE) and certain of its officers. The class action, filed...

ZYNE : 6.58 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 7.08
1st Resistance Point 6.80
Last Price 6.58
1st Support Level 6.36
2nd Support Level 6.20

See More

52-Week High 16.47
Fibonacci 61.8% 11.23
Fibonacci 50% 9.61
Fibonacci 38.2% 7.99
Last Price 6.58
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar